Article

Patient preferences and willingness to pay for arthroplasty surgery in patients with osteoarthritis of the hip.

Department of Orthopaedic Surgery, University of California, San Francisco, CA, USA.
The Journal of arthroplasty (Impact Factor: 2.37). 09/2011; 27(4):503-506.e2. DOI: 10.1016/j.arth.2011.07.007
Source: PubMed

ABSTRACT Little is known about the economic value patients place on effective treatment of osteoarthritis (OA) of the hip. The purpose of this study was to evaluate the value of total hip arthroplasty (THA) and hip resurfacing arthroplasty (HRA) to patients with advanced hip OA by measuring their preferences and willingness to pay (WTP) for either procedure. Seventy-three patients younger than 65 years with advanced hip OA reviewed information about the risks and benefits of THA and HRA and were asked which procedure they would choose and how much they would be willing to pay for it. Sixty-nine percent of patients chose THA (average WTP, $69 419) and 31% chose HRA (average WTP, $83 195). There was no correlation between WTP and annual income or total assets. However, patients with modest income and assets could have reported that they were willing and able to pay more than they could actually afford, and WTP dropped and correlation with income rose if we excluded high responses from the poorest respondents. These results may have important policy implications as patients are asked to share a greater burden of the cost of their care for chronic conditions such as OA.

0 Bookmarks
 · 
73 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: A number of reconstructive procedures are available for the management of hip osteoarthritis. Hip resurfacing arthroplasty is now an accepted procedure, with implant survivorship comparable to THA at up to 10 years' followup in certain series. Most reports focus on implant survivorship, surgeon-derived results, or complications. Fewer data pertain to patient-reported results, including validated measures of quality of life (QoL) and satisfaction and baseline measures from which to determine magnitude of improvement. Validated patient-reported results are essential to guide patients and surgeons in the current era of informed and shared decision making. QUESTIONS/PURPOSES: We determined whether patients reported improvement in disease-specific, joint-specific, and generic QoL after hip resurfacing arthroplasty; whether patients were satisfied with the results of the procedure; and latest activity level and return to sport. METHODS: We retrospectively reviewed 127 patients (100 men, 27 women) who underwent 143 hip resurfacing procedures between 2002 and 2006. Mean patient age was 52 years. Patients completed the WOMAC, Oxford Hip Score, and SF-12 at baseline and again at minimum 2-year followup (mean, 2.5 years; range, 2-6 years). At latest followup, patients completed a validated satisfaction questionnaire and UCLA activity score. RESULTS: All QoL scores improved (normalized to a 0-100 scale, where 100 = best health state). WOMAC improved from 46 to 95, Oxford Hip Score from 42 to 95, SF-12 (physical) from 34 to 54, and SF-12 (mental) from 46 to 56. Patient satisfaction score was 96. UCLA activity score was 8. CONCLUSIONS: The majority of patients reported improvement in QoL, were very satisfied with their outcome, and returned to a high level of activity after hip resurfacing arthroplasty. LEVEL OF EVIDENCE: Level IV, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.
    Clinical Orthopaedics and Related Research 10/2012; · 2.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Numerous disease modifying drugs for osteoarthritis (DMOADs) are under investigation. However, patients' preferences for drugs to prevent progression of OA are not known. The objective of this study was to quantify patient preferences for potential DMOADs. Methods: We administered a conjoint analysis survey to 304 patients attending outpatient general medicine and specialty clinics. All patients seated in the waiting rooms were asked if they would participate in a survey to elicit opinions about arthritis treatments. We performed simulations to estimate preferences for four options to prevent worsening of knee OA: Best Case (pill, highest benefit, lowest risk, lowest cost), Worst Case (infusion, lowest benefit, highest risk, highest cost), Moderate Subcutaneous Injection (injection, lowest benefit, mid-level risk, mid-level cost), and Moderate Infusion (same as previous except administered by infusion). Results: Subjects' median age was 57 years; 55% were female and 69% were Caucasian. Segmentation analyses revealed 4 patterns of preferences. A small minority (5%) who do not want to perform subcutaneous injections and will only consider DMOADs under the Best-Case scenario. Approximately 20% are risk sensitive and are willing to take DMOADs under the Best-Case scenario, but start rejecting these medications as risk increases. A significant number reject DMOADs under all conditions (16.4%); however, the largest segment (59.2%) has a strong preference for DMOADs across all scenarios. Conclusion: Our results suggest that a significant percent of a non-selected outpatient population might be willing to accept at least a moderate degree of risk in order to prevent worsening knee OA. © 2014 American College of Rheumatology.
    Arthritis care & research. 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: As health care organizations adapt to more accountable financial models, it is increasingly important to assess how patients value new technologies, and their willingness to contribute to their cost. A questionnaire described features of a 'standard' implant including its longevity and risk of complications. We asked if participants would be willing to contribute to the cost of 3 novel implants with differing longevity and risk of complications. Our cohort included 195 patients, 45% were willing to add a co-pay to increase the longevity. Willingness to pay decreased to 26% with increased risk of complications, and 29% were willing to pay for a decreased risk of complications. Patients with higher education level, private insurance and males were more willing to contribute for a novel prosthesis. This study demonstrated that 26%-45% of patients are willing to share costs of a novel prosthesis. Willingness to pay was associated with the proposed implant benefits and with patient characteristics.
    The Journal of Arthroplasty 05/2014; · 2.37 Impact Factor